{"id":"https://openalex.org/W7225344097","doi":"https://doi.org/10.5281/zenodo.23976907","title":"The Virtuous Fund: A Patient Capital Vehicle for Genuine Biomedical Discovery","display_name":"The Virtuous Fund: A Patient Capital Vehicle for Genuine Biomedical Discovery","publication_year":2026,"publication_date":"2026-11-05","ids":{"openalex":"https://openalex.org/W7225344097","doi":"https://doi.org/10.5281/zenodo.23976907"},"language":"en","primary_location":{"id":"doi:10.5281/zenodo.23976907","doi":"https://doi.org/10.5281/zenodo.23976907","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23976907","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Preprint"},"volume":null,"type":"preprint","is_traditional":true,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.5281/zenodo.23976907","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5160797881","display_name":"pierre Keraudren","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Keraudren, pierre","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5160797881"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11903","display_name":"Private Equity and Venture Capital","score":0.7461000084877014,"subfield":{"id":"https://openalex.org/subfields/2003","display_name":"Finance"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11903","display_name":"Private Equity and Venture Capital","score":0.7461000084877014,"subfield":{"id":"https://openalex.org/subfields/2003","display_name":"Finance"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.13609999418258667,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T14464","display_name":"Community Development and Social Impact","score":0.04479999840259552,"subfield":{"id":"https://openalex.org/subfields/2003","display_name":"Finance"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/patient-capital","display_name":"patient capital","score":0.9829999804496765},{"id":"https://openalex.org/keywords/drug-discovery","display_name":"drug discovery","score":0.8600000143051147},{"id":"https://openalex.org/keywords/therapeutic-target","display_name":"therapeutic target","score":0.5429999828338623},{"id":"https://openalex.org/keywords/primary-resistance","display_name":"primary resistance","score":0.4740000069141388},{"id":"https://openalex.org/keywords/precision-medicine","display_name":"precision medicine","score":0.7350000143051147},{"id":"https://openalex.org/keywords/immune-mediated-diseases","display_name":"immune-mediated diseases","score":0.7789999842643738},{"id":"https://openalex.org/keywords/investment-governance","display_name":"investment governance","score":0.3709999918937683},{"id":"https://openalex.org/keywords/research-foundations","display_name":"research foundations","score":0.5220000147819519}],"concepts":[{"id":"https://openalex.org/C181190989","wikidata":"https://www.wikidata.org/wiki/Q1200733","display_name":"Divestment","level":2,"score":0.607699990272522},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.5403000116348267},{"id":"https://openalex.org/C27548731","wikidata":"https://www.wikidata.org/wiki/Q88272","display_name":"Investment (military)","level":3,"score":0.4821999967098236},{"id":"https://openalex.org/C183582576","wikidata":"https://www.wikidata.org/wiki/Q184783","display_name":"Market liquidity","level":2,"score":0.45170000195503235},{"id":"https://openalex.org/C39389867","wikidata":"https://www.wikidata.org/wiki/Q380767","display_name":"Corporate governance","level":2,"score":0.4514999985694885},{"id":"https://openalex.org/C83646750","wikidata":"https://www.wikidata.org/wiki/Q193893","display_name":"Capital (architecture)","level":2,"score":0.3896999955177307},{"id":"https://openalex.org/C162118730","wikidata":"https://www.wikidata.org/wiki/Q1128453","display_name":"Actuarial science","level":1,"score":0.36160001158714294},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.34940001368522644},{"id":"https://openalex.org/C69828861","wikidata":"https://www.wikidata.org/wiki/Q2814650","display_name":"Austerity","level":3,"score":0.3321000039577484},{"id":"https://openalex.org/C40700","wikidata":"https://www.wikidata.org/wiki/Q1411783","display_name":"Industrial organization","level":1,"score":0.32580000162124634},{"id":"https://openalex.org/C169549615","wikidata":"https://www.wikidata.org/wiki/Q939134","display_name":"Return on investment","level":3,"score":0.3248000144958496},{"id":"https://openalex.org/C2777146004","wikidata":"https://www.wikidata.org/wiki/Q14949826","display_name":"CLARITY","level":2,"score":0.31940001249313354},{"id":"https://openalex.org/C2777276634","wikidata":"https://www.wikidata.org/wiki/Q211067","display_name":"Conflict of interest","level":2,"score":0.30959999561309814},{"id":"https://openalex.org/C98965940","wikidata":"https://www.wikidata.org/wiki/Q877496","display_name":"Transaction cost","level":2,"score":0.29350000619888306},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.2870999872684479},{"id":"https://openalex.org/C57473165","wikidata":"https://www.wikidata.org/wiki/Q7315604","display_name":"Resistance (ecology)","level":2,"score":0.28290000557899475},{"id":"https://openalex.org/C100001284","wikidata":"https://www.wikidata.org/wiki/Q2248246","display_name":"Public economics","level":1,"score":0.2786000072956085},{"id":"https://openalex.org/C45237549","wikidata":"https://www.wikidata.org/wiki/Q1376796","display_name":"Restructuring","level":2,"score":0.2759999930858612},{"id":"https://openalex.org/C2992293740","wikidata":"https://www.wikidata.org/wiki/Q4781752","display_name":"Drug approval","level":3,"score":0.2736999988555908},{"id":"https://openalex.org/C2985722716","wikidata":"https://www.wikidata.org/wiki/Q4290","display_name":"Capital investment","level":2,"score":0.26350000500679016},{"id":"https://openalex.org/C172497479","wikidata":"https://www.wikidata.org/wiki/Q302208","display_name":"Capital expenditure","level":2,"score":0.26339998841285706},{"id":"https://openalex.org/C2992823438","wikidata":"https://www.wikidata.org/wiki/Q490513","display_name":"International investment","level":3,"score":0.2619999945163727},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.2615000009536743},{"id":"https://openalex.org/C28719098","wikidata":"https://www.wikidata.org/wiki/Q44946","display_name":"Point (geometry)","level":2,"score":0.2549000084400177},{"id":"https://openalex.org/C2778012447","wikidata":"https://www.wikidata.org/wiki/Q1034415","display_name":"Scope (computer science)","level":2,"score":0.2540999948978424}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.5281/zenodo.23976907","doi":"https://doi.org/10.5281/zenodo.23976907","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23976907","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Preprint"},{"id":"doi:10.5281/zenodo.23976908","doi":"https://doi.org/10.5281/zenodo.23976908","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23976908","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Preprint"}],"best_oa_location":{"id":"doi:10.5281/zenodo.23976907","doi":"https://doi.org/10.5281/zenodo.23976907","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23976907","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Preprint"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.6240000128746033}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7167683629","https://openalex.org/W6903700707","https://openalex.org/W2408282947","https://openalex.org/W142555550","https://openalex.org/W2410707541","https://openalex.org/W2463562395","https://openalex.org/W2398058426","https://openalex.org/W2443705118","https://openalex.org/W2409142937","https://openalex.org/W7071713162"],"abstract_inverted_index":{"An":[0],"independent":[1,83,90],"analysis":[2],"of":[3,25,77],"a":[4,19,38,74,88],"structural":[5],"gap":[6],"in":[7],"biomedical":[8,97],"financing:":[9],"nine":[10],"therapeutic":[11,50],"targets":[12],"validated":[13],"and":[14,56,73],"competed":[15],"to":[16,81],"near-exhaustion":[17],"within":[18],"single":[20],"inflammatory":[21],"cascade,":[22],"while":[23],"mechanisms":[24,66],"primary":[26],"resistance":[27],"remain":[28],"underfunded.":[29],"The":[30],"paper":[31],"proposes":[32],"an":[33,69,82],"evergreen,":[34],"patient-capital":[35],"fund":[36],"with":[37],"three-tier":[39],"governance":[40],"structure":[41],"(foundation,":[42],"holding,":[43],"programmes)":[44],"allocating":[45],"capital":[46],"across":[47],"four":[48],"axes:":[49],"rescue,":[51],"precision":[52],"medicine,":[53],"etiological":[54],"discovery":[55],"European":[57,104],"manufacturing":[58],"sovereignty.":[59],"It":[60],"describes":[61],"the":[62],"investment":[63],"criteria,":[64],"liquidity":[65],"for":[67],"investors,":[68],"indicative":[70],"return":[71],"profile,":[72],"fixed":[75],"share":[76],"divestiture":[78],"proceeds":[79],"directed":[80],"research":[84,98],"foundation.":[85],"This":[86],"is":[87],"non-peer-reviewed":[89],"analysis.":[91],"Keywords:":[92],"patient":[93],"capital;":[94],"evergreen":[95],"fund;":[96],"financing;":[99],"drug":[100],"discovery;":[101],"pharmaceutical":[102],"manufacturing;":[103],"sovereignty;":[105],"immune-mediated":[106],"diseases":[107]},"counts_by_year":[],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2026-11-06T00:00:00"}